| Literature DB >> 28962198 |
Jichang Wang1, Boxiang Zhang2, Jinying Meng3, Guodong Xiao2, Xiang Li2, Gang Li2, Sida Qin2, Ning Du2, Jia Zhang2, Jing Zhang2, Chongwen Xu4, Shou-Ching Tang5,6, Rui Liang7, Hong Ren2, Xin Sun2.
Abstract
Evaluating the clinicopathological features of patients receiving definitive treatment for esophageal cancer may facilitate the identification of patterns and factors associated with post-operative complications, and enable the development of a surveillance strategy for surviving patients at a higher risk of disease recurrence. In the present study, clinical data from 579 patients with esophageal cancer that underwent radical resection of esophagus were collected. These patients were admitted to two medical centers in Northwest China, and information regarding the presence or absence of basic chronic diseases and post-operative results were retrospectively analyzed. The level of selected stem cell markers, including aldehyde dehydrogenase 1, CD133, integrin subunit α 6, integrin subunit β 4 and T-cell factor-4, were determined in esophageal cancer tissue samples in order to determine whether these markers may be useful predictors of disease prognosis and recurrence. Post-operative complications in patients receiving radical resection of the esophagus included respiratory system complications, cardiovascular abnormalities and esophageal anastomotic fistulae. Diabetes, basic respiratory disease and lower pre-surgical serum albumin levels were observed to be individual risk factors associated with post-operative complications, including respiratory system complications of acute respiratory failure and pulmonary infection, cardiovascular abnormalities of atrial fibrillation and arrhythmia, as well as the development of esophageal anastomotic fistulae. Diagnosis of esophageal cancer at later stage was significantly correlated with anastomotic fistula. Molecular detection of stem cell markers for prognosis prediction was achieved by immunohistochemical and immunofluorescence staining assays. The results demonstrated that the presence of stem-like cells in cancer tissues was associated with poor disease prognosis and a high recurrence ratio. In conclusion, the results of the current study suggested that post-operative complications were more likely to occur in patients with diabetes, basic respiratory disease or lower serum albumin levels prior to surgery. Therefore, sufficient intensive peri-operative care, rigorous operative risk assessments, and the selection of the patients with early or mid-stage esophageal cancer, may decrease the risk of post-surgical complications in patients receiving radical resection of the esophagus. In addition, a high ratio of esophageal cancer stem-like cells was associated with cancer recurrence. These results suggest that an intensive surveillance strategy should be implemented in order to facilitate early detection of disease recurrence and improve the clinical management of these patients post-surgery.Entities:
Keywords: anastomotic fistula; cancer stem-like cells; esophageal cancer; post-operative complications; prognosis prediction
Year: 2017 PMID: 28962198 PMCID: PMC5609247 DOI: 10.3892/etm.2017.4835
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Clinicopathological features of enrolled patients with esophageal cancer that underwent radical esophagectomy.
| Feature | Number |
|---|---|
| Sex (male/female) | 475/104 |
| Median age (years) | 56 |
| <65 years | 239 |
| ≥65 years | 340 |
| Diabetes type II (Y/N) | 108/471 |
| Hypertension (Y/N) | 202/377 |
| Location of tumor in esophagus | |
| Upper | 69 |
| Middle | 302 |
| Lower | 208 |
| Histological type | |
| SC | 499 |
| AC | 71 |
| AS | 9 |
| Neoadjuvant or adjuvant therapy (Y/N) | 425/154 |
| Pathological tumor stage | |
| I | 51 |
| II | 262 |
| III | 251 |
| IV | 15 |
| Respiratory complications (Y/N) | 304/275 |
| Operation time (h) | |
| <4 | 163 |
| ≥4 | 416 |
| Anastomotic fistula (Y/N) | 46/533 |
SC, squamous carcinoma; AC, adenocarcinoma; AS, adenosquamous carcinoma; RE, radical esophagectomy.
Geographical distribution of enrolled patients.
| Geographical location | Hospital 1 | Hospital 2 | Total (%) |
|---|---|---|---|
| Northern Shaanxi | 95 | 41 | 136 (23.5) |
| Guanzhong region | 17 | 11 | 28 (4.8) |
| Southern Shaanxi | 113 | 38 | 151 (26.1) |
| Shanxi province | 36 | 3 | 39 (6.7) |
| Henan province | 20 | 5 | 25 (4.3) |
| The Ningxia Hui autonomous region | 55 | 3 | 58 (10.0) |
| Gansu province | 48 | 7 | 55 (9.5) |
| Sichuan province | 19 | 0 | 19 (3.3) |
| Qinghai province | 46 | 5 | 51 (8.8) |
| Additional provinces | 15 | 2 | 17 (2.9) |
| Total | 464 | 115 | 579 (100.0) |
Hospital 1, The First Affiliated Hospital of Xi'an Jiaotong University; Hospital 2, The Second Affiliated Hospital of Xi'an Jiaotong University.
Figure 1.The geographical distribution patterns of enrolled patients. The origins of enrolled patients were indicated with a black tick or a filled black circle. The relative geographical distribution of enrolled patients in indicated in a pie chart, and the majority of enrolled patients that received an esophagectomy were from Northern and Southern Shaanxi province, where individuals tend to consume a diet rich in pickled and solid food with low fiber content.
Respiratory system complications in patients with that underwent a radical esophagectomy (n=579).
| A, Atelectasis/ARF | |||
|---|---|---|---|
| Feature | Patients with | Patients without | P-value |
| Sex (male/female) | 2/3 | 473/101 | 0.014 |
| Age (<65/≥65 years) | 1/4 | 238/336 | 0.332 |
| Diabetes type II (Y/N) | 5/0 | 103/471 | <0.001 |
| Hypertension (Y/N) | 1/4 | 201/373 | 0.483 |
| URD (Y/N) | 4/1 | 300/274 | 0.216 |
| DO (<4/≥4 h) | 1/4 | 162/412 | 0.684 |
| BF (Y/N) | 1/4 | 14/560 | 0.014 |
| EAS (Y/N) | 4/1 | 42/532 | <0.001 |
| B, Pneumonia/empyema | |||
| Feature | Patients with | Patients without | P-value |
| Sex (male/female) | 25/6 | 450/98 | 0.835 |
| Age (<65/≥65 years) | 11/20 | 228/320 | 0.501 |
| Diabetes type II (Y/N) | 21/10 | 87/461 | <0.001 |
| Hypertension (Y/N) | 13/18 | 189/359 | 0.397 |
| URD (Y/N) | 28/3 | 276/272 | <0.001 |
| DO (<4/≥4 h) | 6/25 | 157/391 | 0.263 |
| BF (Y/N) | 7/24 | 8/540 | <0.001 |
| EAS (Y/N) | 24/7 | 22/526 | <0.001 |
ARF, acute respiratory failure; URD, underlying respiratory diseases; DO, duration of operation; BF, bronchopleural fistulae; EAS, esophageal anastomotic fistulae.
Post-operative cardiovascular disorders in study participants.
| A, Atrial fibrillation | |||
|---|---|---|---|
| Feature | Patients with | Patients without | P-value |
| Sex (male/female) | 32/19 | 443/85 | <0.001 |
| Age (<65/≥65 years) | 12/39 | 227/301 | 0.007 |
| Hypertension (Y/N) | 36/15 | 166/362 | <0.001 |
| URD (Y/N) | 30/21 | 274/254 | 0.344 |
| DO (<4/≥4 h) | 15/36 | 148/380 | 0.834 |
| BF (Y/N) | 11/40 | 4/524 | <0.001 |
| EAS (Y/N) | 17/34 | 29/499 | <0.001 |
| B, Arrhythmia | |||
| Feature | Patients with | Patients without | P-value |
| Sex (male/female) | 23/7 | 452/97 | 0.431 |
| Age (<65/≥65 years) | 10/20 | 229/320 | 0.364 |
| Hypertension (Y/N) | 21/9 | 181/368 | <0.001 |
| URD (Y/N) | 15/15 | 289/260 | 0.778 |
| DO (<4/≥4 h) | 8/22 | 155/394 | 0.853 |
| BF (Y/N) | 2/28 | 13/536 | 0.149 |
| EAS (Y/N) | 8/22 | 38/511 | <0.001 |
AF, atrial fibrillation; URD, underlying respiratory diseases; DO, duration of operation; BF, bronchopleural fistulae; EAS, esophageal anastomotic fistulae.
Factors associated with the development of anastomotic fistula following radical esophagectomy.
| Feature | Acceptable recovery | Fistula | Total | Fistula/total (%) | P-value |
|---|---|---|---|---|---|
| Sex | 0.487 | ||||
| Male | 439 | 36 | 475 | 7.6 | |
| Female | 94 | 10 | 104 | 9.6 | |
| Age (years) | 0.119 | ||||
| <65 | 225 | 14 | 239 | 5.9 | |
| ≥65 | 308 | 32 | 340 | 9.4 | |
| Diabetes type II (Y/N) | 91/442 | 17/29 | 108/471 | 15.7/6.2 | <0.001 |
| Hypertension (Y/N) | 183/350 | 19/27 | 202/377 | 9.4/7.2 | 0.341 |
| PreLSA (g/l) | <0.001 | ||||
| <35 | 227 | 33 | 260 | 12.7 | |
| ≥35 | 306 | 13 | 319 | 4.1 | |
| PosLSA (g/l) | 0.093 | ||||
| <35 | 97 | 19 | 116 | 16.3 | |
| ≥35 | 236 | 27 | 463 | 5.8 | |
| URD (Y/N) | 281/252 | 23/23 | 304/275 | 7.6/8.4 | 0.723 |
| PSI | 0.802 | ||||
| 1 | 125 | 12 | 137 | 8.8 | |
| 2 | 305 | 24 | 329 | 7.3 | |
| 3 | 103 | 10 | 113 | 8.8 | |
| DO (h) | 0.166 | ||||
| <4 | 146 | 17 | 163 | 10.4 | |
| ≥4 | 387 | 29 | 416 | 7.0 | |
| HT | 0.105 | ||||
| SC | 463 | 36 | 499 | 7.2 | |
| AC+AS | 70 | 10 | 80 | 12.5 | |
| PTS | <0.001 | ||||
| I | 46 | 5 | 51 | 9.8 | |
| II | 236 | 26 | 262 | 9.9 | |
| III+IV | 251 | 15 | 266 | 5.6 |
PreLSA, preoperative level of serum albumin; PosLSA, postoperative level of serum albumin; URD, underlying respiratory diseases; PSI, patterns of surgery incision; DO, duration of operation; HT, histological type; SC, squamous carcinoma; AC, adenocarcinoma; AS, adenosquamous carcinoma; PTS, pathological tumor stage.
Figure 2.Disease recurrence following curative esophagectomy with radical lymph node dissection. Time-course of disease recurrence following the radical esophagectomy (left plot), and the number of patients that developed disease recurrence each month (right plot). Recurrence was defined as esophageal tumor development within 2 years following the surgical procedure.
Association between clinicopathological features, stem cell marker expression and disease recurrence following radical esophagectomy.
| Recurrence | ||||
|---|---|---|---|---|
| Feature | Yes | No | P-value | χ2 |
| Histological type | ||||
| SC | 171 | 328 | <0.0001 | 20.000 |
| AC | 41 | 30 | ||
| AS | 0 | 9 | ||
| Neoadjuvant/adjuvant therapy (Y/N) | 117/95 | 308/59 | <0.0001 | N/A |
| Pathological tumor stage | ||||
| I | 7 | 44 | <0.0001 | 93.241 |
| II | 55 | 207 | ||
| III | 136 | 115 | ||
| IV | 14 | 1 | ||
| Relative ALDH intensity | ||||
| +/++ | 51 | 9 | 0.0276 | 7.179 |
| +++ | 21 | 10 | ||
| ++++ | 9 | 7 | ||
| Relative CD133 intensity | ||||
| +/++ | 38 | 6 | 0.0244 | 7.427 |
| +++ | 29 | 14 | ||
| ++++ | 23 | 15 | ||
| Relative ITGA6 intensity | ||||
| +/++ | 31 | 4 | 0.0856 | 4.916 |
| +++ | 26 | 10 | ||
| ++++ | 8 | 5 | ||
| Relative ITGB4 intensity | ||||
| +/++ | 29 | 5 | 0.0514 | 5.938 |
| +++ | 16 | 11 | ||
| ++++ | 19 | 11 | ||
| Relative TCF-4 intensity | ||||
| + | 21 | 2 | 0.0313 | 8.851 |
| ++ | 32 | 6 | ||
| +++ | 42 | 23 | ||
| ++++ | 10 | 3 | ||
SC, squamous carcinoma; AC, adenocarcinoma; AS, adenosquamous carcinoma; ALDH, aldehyde dehydrogenase 1; ITGA6, integrin subunit α 6; ITGB4, integrin subunit β 4; TCF-4, T-cell factor-4.
Figure 3.Clinicopathological features potentially associated with disease recurrence following curative esophagectomy with radical lymph node dissection. (A) Histological type, (B) neoadjuvant or adjuvant therapy and (C) pathological stage were assessed for their potential association with disease recurrence. Patients grouped by disease recurrence demonstrated significant differences among these three clinicopathological features. SC, squamous carcinoma; AC, adenocarcinoma; AS, adenosquamous carcinoma.
Figure 4.Evaluating the role of stemness markers in predicting disease recurrence. A cohort of stem cell markers was assessed for their potential role in predicting disease recurrence within 2 years following curative esophagectomy with radical lymph node dissection. The relative staining intensities of (A) ALDH1, (B) CD133 (C) and TCF-4 were determined. Representative images of immunohistochemical staining for (D) ALDH1, (E) CD133, and (F) representative images of immunofluorescence staining for ALDH1 and TCF-4 are presented. ALDH1, aldehyde dehydrogenase 1; TCF-4, T-cell factor-4.